前列腺癌的血统可塑性取决于JAK/STAT炎症信号
Joseph M Chan1,2, Samir Zaidi3,4, Jillian R Love3
1Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
概括
癌症药物耐药性涉及细胞的可塑性. 这项研究显示前列腺癌的耐药性取决于混合系细胞中的Janus激酶 (JAK) 和纤维细胞生长因子受体 (FGFR) 信号.
科学领域:
- 癌症学
- 分子生物学
- 癌症研究
背景情况:
- 癌症的耐药性,特别是前列腺癌,是一个重大的临床挑战.
- 瘤细胞状态和血统可塑性与耐药性有关,但潜在的分子机制尚未完全理解.
研究的目的:
- 在前列腺癌中研究血统可塑性的分子驱动.
- 研究血统可塑性与抗雄激素耐药性之间的关系.
主要方法:
- 使用了小鼠器官和基因工程小鼠模型.
- 使用患者衍生自割抵抗性前列腺癌的器官培养物.
- 进行单细胞分析以确定细胞群和信号通路.
主要成果:
- 确定了一种特定的上皮细胞群体,具有混合的光基因表型作为可塑性的来源.
- 证明增加的 Janus 激酶 (JAK) 和纤维细胞生长因子受体 (FGFR) 活动驱动这种可塑性.
- 观察到抑制患者衍生器官中的JAK和FGFR信号可提高光线基因表达,证实了依赖性.
结论:
- 前列腺癌的血统可塑性是由混合的光基因表型细胞启动的,并且依赖于JAK和FGFR信号传递.
- 在转移性抵抗割的前列腺癌患者中存在具有激活的JAK/ STAT和FGFR信号的混合系细胞.
- 这些发现对针对JAK和FGFR途径的临床试验中的患者分层有影响.
相关概念视频
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
MAPK Signaling Cascades
5.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K


